http://www.eurekale rt.org/pub_ releases/ 2009-06/slu- gnf061509. php

Public release date: 16-Jun-2009
Contact: Carrie Bebermeyer
bebermcl@slu. edu
314-398-5279
Saint Louis University

Good news for some hard-to-treat hepatitis C patients

SLU researcher tests new treatment for virus
ST. LOUIS – In a multi-center trial led by a Saint Louis University
researcher, investigators found that a new combination therapy of daily
consensus interferon and ribavirin helps some hepatitis C patients who have not
responded to previous treatment. The findings, published in the June issue of
Hepatology, offer a new option for hepatitis C patients, and may be effective
even for those patients with factors that make their condition difficult to
treat.
"This represents an important advance for difficult to treat hepatitis C
patients who have failed to respond to traditional therapy," said Bruce Bacon,
M.D., director of the division of gastroenterology and hepatology at Saint Louis
University School of Medicine and co-director of the Saint Louis University
Liver Center .
About 4 million people in the U.S. have been infected with hepatitis C; an
estimated 10,000 to 12,000 people die from complications each year in this
country. Hepatitis C is caused by a virus, transmitted by contact with blood,
and may initially be asymptomatic. For patients who develop chronic hepatitis C
infection, inflammation of the liver may develop, leading to fibrosis and
cirrhosis (scarring of the liver), as well as other complications including
liver cancer and death.
For patients with chronic hepatitis C, the prognosis varies. About half fully
recover after an initial course of pegylated interferon and ribavirin anti-viral
therapy that may last from six months to a year.
The remaining patients, known as non-responders, may improve but the virus is
not eliminated. These patients are at greatest risk for worsening, and
subsequent treatments have shown limited effectiveness for this group. In
addition, those with genotype 1 (a particular genetic variation of the virus),
those with high baseline virus levels, those with advanced liver disease and
African American patients are all less likely to respond well to treatment.
The study looked at 515 patients at 44 different sites. Patients were given
either one of two doses of daily consensus interferon and ribavirin, or no
treatment.
For patients with less severe liver damage who had shown some response to
initial treatment, the success rate was above 30 percent. The overall results
showed that, for patients who had been unresponsive to initial treatment,
consensus interferon and ribavirin worked for about 7 percent of patients given
the lower dose and about 11 percent of patients given the higher dose of
consensus interferon and ribavirin.
"This study shows that select patients who have failed to respond to prior
therapy are candidates for retreatment with consensus interferon and ribavirin,"
Bacon said.

###
The study, Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined
Therapy (DIRECT) was funded by Valeant Pharmaceuticals and 3 Rivers
Pharmaceuticals.
Established in 1836, Saint Louis University School of Medicine has the
distinction of awarding the first medical degree west of the Mississippi River.
The school educates physicians and biomedical scientists, conducts medical
research, and provides health care on a local, national and international level.
Research at the school seeks new cures and treatments in five key areas: cancer,
liver disease, heart/lung disease, aging and brain disease, and infectious
disease.


[Non-text portions of this message have been removed]